Anti-Beta (β)-Amyloid antibody

The cerebral and vascular plaques associated with Alzheimer′s disease (AD) are mainly composed of amyloid beta peptides (Ab). Ab is derived from cleavage of the amyloid precursor protein (APP) and varies in length from 39 to 43 amino acids. Ab [1-40], Ab [1-42], and Ab [1-43] peptides result from cleavage of APP after residues 40, 42, and 43, respectively. The cleavage takes place by gamma-secretase during the last APP processing step. Ab [1-40], [1-42] and [1-43] peptides are major constituents of the plaques and tangles that occur in AD. Ab antibodies and peptides have been developed as tools for elucidating the biology of AD.

A six amino acid peptide sequence from the C-terminal of human beta-amyloid 1-42.

Epitope: C-terminus

Anti-Beta-Amyloid 1-42 Antibody is an antibody against Beta-Amyloid 1-42 for use in ELISA, IH, IH(P) & WB.

Immunohistochemistry (Paraffin) Analysis:

Western Blot:
1-10 µg/mL of a previous lot was used. (Chemiluminescence technique).

ELISA:
1:10,000-1:100,000 of a previous lot was used using 50-100 ng immunogen peptide/well.

Optimal working dilutions must be determined by the end user.

Research Category
Neuroscience

Research Sub Category
Neurodegenerative Diseases

Recognizes beta-amyloid 1-42. Antibody does not show appreciable reactivity with beta amyloid 1-40 as detected by ELISA.
One of the most important and initial steps which causes loss of memory and cognition in Alzheimer’s Disease (AD) involves proteolytic cleavage of amyloid precursor protein (APP, chromosome 21) releasing short 40, 42 & 43 amino acid peptides (beta amyloid 1-40, 1-42 and 1-43). Polymerization of beta-amyloid and subsequent neuronal deposit (amyloid) leads to the degeneration of neurons involved in memory and cognition.

ImmunoAffinity Purified

Purified rabbit polyclonal in liquid buffer containing PBS with 0.1% BSA.

Stable for 1 year at -20ºC from date of receipt.

Control
Alzheimer′s disease brain tissue, whole tissue extracts from mouse brain. C03-801.

Routinely evaluated by immunohistochemistry (paraffin) on Alzheimer’s Disease-Brain.

Immunohistochemistry (Paraffin) Analysis:
Beta-Amyloid (cat. # AB5078P) staining on Alzheimer’s Disease-Brain. Tissue pretreated with Citrate, pH 6.0. The antibody was diluted to 1:35, using IHC-Select Detection with HRP-DAB. Immunoreactivity is seen as staining on plaque deposits (brown) or as cerebral vascular amyloid deposition in the walls of blood vessels (brown).

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.